[4]PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Abstract 11.Oral Abstract Session [5]Noel Clarke, et al. Abiraterone and Olaparib for ...
[4]PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Abstract 11.Oral Abstract Session [5]Noel Clarke, et al. Abiraterone and Olaparib for ...
[4]PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo (pbo) and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Abstract 11.Oral Abstract Session [5]Noel Clarke, et al. Abiraterone and Olaparib for ...
The prognostic significance of germline variants in homologous recombination repair genes in advanced prostate cancer (PCa), especially with regard to hormonal therapy, remains controversial. Methods Germline DNA from 549 Japanese men with metastatic and/or castration-resistant PCa was sequenced for 27 ca...
Testing for germline BRCA1/2 mutations has an established predictive role in breast cancer risk assessment. More recently, studies have also identified BRCA1/2 status as clinically relevant in the selection of therapy for patients already diagnosed with
BRCA1/2reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.doi:10.1200/JCO.2024.42.16_suppl.50563215056#Background:In prostate cancer (PCA),BRCA1/2alterations confer sensitivity to PARPi; however, in cases other than PCA with ...
22、f brca1 and brca2 mutation carriersj.oncologist,2016,21(7):869-874.12 gallagher d j,cronin a m,milowsky m i,et al.germline brca mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancerj.bju international,2012,109(5):713-719.13...
Breast cancer Professional Committee of Precision Therapy Committee of Chinese Medical Doctor Association, Breast Cancer Group of Cancer Branch of Chinese Medical Association, Breast Cancer Professional Committee of China Anti-Cancer...
Breast cancer Professional Committee of Precision Therapy Committee of Chinese Medical Doctor Association, Breast Cancer Group of Cancer Branch of Chinese Medical Association, Breast Cancer Professional Committee of China Anti-Cancer Association, et al. Expert consensus on BRCA1/2 gene detection and clini...
ObservationsThis narrative review summarized the data that inform cancer risks, targeted cancer therapy options, and guidelines for early cancer detection. It also highlighted areas of emerging research and clinical trial opportunities for maleBRCA1/2PV carriers. These developments, along with the continu...